Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2023-08-14 English
At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended ....
Regulatory Filings
2023-08-14 English
At the Board Meeting of the Company held on Monday, August 14, 2023, the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended ....
Regulatory Filings
2023-08-14 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement addressed to stock exchanges (BSE and NSE) about the launch of a pharmaceutical product (Selumetinib capsules) by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval but primarily serves as a notification of the product launch. There is no financial data, no report attached or referenced, and no indication of a meeting, voting, or management change. The document is brief (1341 characters) and is an update to the market rather than a formal report or filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-09 English
We refer to our earlier communication dated September 26, 2021 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib ....
Regulatory Filings Classification · 95% confidence The document is a short announcement addressed to stock exchanges (BSE and NSE) regarding the launch of a pharmaceutical product (Selumetinib capsules) by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval but primarily serves as a notification of a product launch. The document is brief (1341 characters) and does not contain financial data, detailed financial performance, or regulatory filings related to financial results or governance. It is not an annual report, earnings release, or any detailed financial or governance report. It is also not a voting result, director dealing, or capital change announcement. The content is a corporate announcement to stock exchanges about a business update (product launch). Given the nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-09 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about an upcoming Board of Directors meeting scheduled for August 14, 2023, to consider and approve the unaudited financial results for the quarter ended June 30, 2023. It also mentions the closure of the trading window for insiders. The document does not contain any financial data or detailed results itself, nor does it include a full report. It is an announcement related to a board meeting and financial results approval, not the results or report itself. The length is only 1483 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this fits best under Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2023-08-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.